Tuesday 19th April 2016
Sharing Data to Improve Lives: The SRUK Patient Registry Survey
SRUK is developing a Patient Registry, with the aim of improving outcomes for people diagnosed with Scleroderma or Raynaud's. Our Registry will be a secure, anonymous database, containing health information about people living with the conditions. It will be used to improve our understanding of Scleroderma and Raynaud's and how different people are affected over time, to help accelerate research into new and better treatments designed to improve quality of life. Read on to find out what we learned through the SRUK Patient Registry Survey, and how it will help shape our Patient Registry.
SRUK's response to the Autumn Statement
SRUK asks the Chancellor to consider the impact of changes to disability benefits on people with scleroderma and we renew our call for more support with energy bills for those that need it most.
Government must expand Cost of Living Payments to protect health of those living with Raynaud's Phenomenon
Ahead of the Chancellor's Autumn Statement we are calling on the government to expand its Cost of Living Payment criteria to include people living with Raynaud’s Phenomenon.
Friday 15th April 2016
How I Manage My Auto Immune Diseases Without Medication
Well! It’s not easy but I have managed it with a few changes over the years to my nutrition and a good exercise plan.
Thursday 14th April 2016
What Exactly is 'Pre-Scleroderma'?
Tuesday 12th April 2016
Endothelin-1 Receptor Blockers Again Shown to Be Ineffective in Treating Skin Fibrosis
Saturday 2nd April 2016
What is research doing for me?
Prof. Denton, Consultant Rheumatologist at the Royal Free Hospital, London opened the World Systemic Sclerosis Congress with a presentation on 'What is research doing for me?' This uplifting and informative presentation highlighted the positive breakthroughs taking place in scleroderma research.
Wednesday 30th March 2016
Halfway Point Marked in Scleroderma Patient Enrolment for Cytori's ECCS-50 Phase 3 Trial
Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment.